transthyretin amyloid cardiomyopathy
Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues
Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues
Bayer’s Kerendia granted FDA approval for new heart failure indication
Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%
Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours
The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway
FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate
The progressive neurodegenerative disease affects more than ten million people worldwide
Bayer UK launches digital educational hub to improve menopause support
An estimated 13 million women in the UK are currently perimenopausal or menopausal
Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial
Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy
FDA approves BridgeBio Pharma’s Attruby to treat rare heart disease ATTR-CM
Transthyretin amyloid cardiomyopathy affects up to 500,000 people worldwide
Bayer presents positive results for Kerendia in late-stage heart failure study
Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%
Bayer and NextRNA Therapeutics enter oncology partnership worth $547m
The companies will advance small molecule therapeutics against a new class of targets for cancer
Bayer shares promising results for Kerendia in phase 3 heart failure study
Approximately 55% of heart failure patients have an LVEF of at least 40%
Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial
The results from the study will support regulatory applications for wider use of the drug
Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study
Vasomotor symptoms are reported by up to 80% of women during the menopausal transition